and sulfamethazine failed to bear labeling containing adequate warnings against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and methods and duration of administration, in such manner and form, as are necessary for the protection of users.

DISPOSITION: April 2, 1953. A plea of nolo contendere having been entered, the court fined the defendant $300.

4067. Misbranding of diethylstilbestrol tablets, dextro-amphetamine sulfate tablets, and capsules containing a mixture of pentobarbital and carbromal. U. S. v. Thomas Daniels. Plea of nolo contendere. Fine, $300. (F. D. C. No. 33744. Sample Nos. 31031–L, 31032–L, 31036–L, 31037–L, 32349–L, 34181–L.)

INFORMATION FILED: January 22, 1953, Western District of Missouri, against Thomas Daniels, a clerk employed at the Wooten Drug Co., Aurora, Mo.

ALLEGED VIOLATION: On or about March 20, 25, and 26, 1952, while a number of *diethylstilbestrol tablets, dextro-amphetamine sulfate tablets,* and *capsules containing a mixture of pentobarbital and carbromal* were being held for sale at the Wooten Drug Co., after shipment in interstate commerce, the defendant caused various quantities of the drugs to be repacked and dispensed without a physician's prescription, which acts resulted in the repackaged drugs being misbranded.

NATURE OF CHARGE: Misbranding, Sections 502 (b) (1) and (2), the repackaged drugs failed to bear labels containing the name and place of business of the manufacturer, packer, or distributor, and an accurate statement of the quantity of the contents; and, Section 502 (f) (1), the labeling of the repackaged drugs failed to bear adequate directions for use.

Further misbranding, Section 502 (d), the repackaged capsules contained a mixture of carbromal, a hypnotic substance, and pentobarbital, a chemical derivative of barbituric acid, which derivative has been found to be, and by regulations designated as, habit forming; and the label of the repackaged capsules failed to bear the name, and quantity or proportion of such substance and derivative and in juxtaposition therewith the statement "Warning—May be habit forming." Further misbranding, Section 502 (e) (2), the label of the repackaged capsules failed to bear the common or usual name of each active ingredient of the capsules.

DISPOSITION: April 2, 1953. The defendant having entered a plea of nolo contendere, the court fined him $300.

4068. Misbranding of lozenges of Sulfonamets with Topicaine and dextro-amphetamine sulfate tablets. U. S. v. Henley C. Suddreth (Standard Drug Stores No. 2). Plea of nolo contendere. Fine, $75. (F. D. C. No. 34839. Sample Nos. 3522–L, 3530–L, 3532–L.)

INFORMATION FILED: March 31, 1953, Eastern District of North Carolina, against Henley C. Suddreth, trading as Standard Drug Stores No. 2, Kinston, N. C.

ALLEGED VIOLATION: On or about March 4 and April 23, 1952, while a number of lozenges of *Sulfonamets with Topicaine* and *dextro-amphetamine sulfate tablets* were being held for sale at Standard Drug Stores No. 2, after shipment in interstate commerce, the defendant caused various quantities of the drugs to be repacked and dispensed without a physician's prescription, which acts resulted in the repackaged drugs being misbranded.

NATURE OF CHARGE: Misbranding, Sections 502 (b) (1) and (2), the repackaged drugs failed to bear labels containing the name and place of business of the packer or distributor and an accurate statement of the quantity of the contents; and, Sections 502 (f) (1) and (2), the labeling of the repackaged drugs failed to bear adequate directions for use and adequate warnings against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and methods and duration of administration, in such manner and form, as are necessary for the protection of users.

Further misbranding, Section 502 (e) (2), the repackaged lozenges of *Sulfonamets with Topicaine* failed to bear a label containing the common or usual name of each active ingredient of the drug.

DISPOSITION: April 13, 1953. The defendant having entered a plea of nolo contendere, the court fined him $75.

4069. Misbranding of Fosfarsinol, Cordial Matisura, and Sanqrinol. U. S. v. 70 Cartoned Bottles, etc. (F. D. C. No. 34645. Sample Nos. 50842–L to 50844–L, incl.)

LIBEL FILED: February 3, 1953, Southern District of New York.

ALLEGED SHIPMENT: On or about November 26 and December 3, 1952, by the American Tropical Remedy Co., from Santurce, P. R.

PRODUCTS: 70 cartoned bottles of *Fosfarsinol*, 70 cartoned bottles of *Cordial Matisura*, and 34 cartoned bottles of *Sanqrinol* at New York, N. Y.

LABEL, IN PART: (Carton) "Fosfarsinol * * * Contains Strychnine Glycerophosphate and Vitamin B_1 * * * Each adult dose, one tablespoonful (approximately 15 cc.) contains: Alcohol 13.3% Strychnine Glycerophosphate 0.001 Gm. Thiamine Hydrochloride (Vitamin B_1) 0.005 Gm. Arrhenal 0.010 Gm. Sodium Glycerophosphate 0.300 Gm. Calcium Glycerophosphate 0.130 Gm. Aromatic Vehicle, sufficient quantity to make volume. Fosfarsinol is prescribed by physicians in those conditions in which it is indicated by the therapeutic properties of the medicinal ingredients it contains"; "Cordial Matisura * * * (Formerly Matricura) Alcohol 15.7% * * * Each dose of the Matisura Cordial, one tablespoonful (approximately 15 c. c.) contains: Viburnum Prunifolium 0.50 Gm. Mitchella Repens 0.50 Gm. Aletris Farinosa 0.25 Gm. Alcohol 2.35 c. c. Vehicle, sufficient quantity to make 15 c. c. Cordial Matisura Exclusive Tonic For The Woman"; and "Sanqrinol * * * (Formerly Sangrinol) Alcohol 13.3% * * * Each adult dose, one tablespoonful (approximately 15 c. c.) contains: Iron and Ammonium Citrate 0.500 Gm. Sodium Glycerophosphate 0.500 Gm. Arrhenal 0.010 Gm. Strychnine Glycerophosphate 0.001 Gm. Alcohol 2 c. c. Vehicle, sufficient quantity to make 15 c. c. Sanqrinol is an hematinic prescribed by physicians in those conditions indicated by the therapeutical properties of the medicinal ingredients it contains * * * Warning: Contains Strychnine Do not exceed stated dose."

NATURE OF CHARGE: *Fosfarsinol* and *Sanqrinol*. Misbranding, Section 502 (e) (2), the articles were fabricated from two or more ingredients and their labels failed to bear the common or usual name of each active ingredient since "Arrhenal" is not the common or usual name of the active ingredient, methanearsonic acid, and the labels of the articles failed also to disclose that such ingredient was a derivative of arsenic; and, Section 502 (f) (2), the labelings of the articles failed to bear such adequate warnings against use in those pathological conditions where their use may be dangerous to health, and against unsafe dosage and duration of administration, in such manner